Abstract
Background
Severe acute exacerbation of chronic hepatitis B can sometimes occur and lead to hepatic failure and death. The objective of this study was to elucidate the predictors of progression to hepatic decompensation during severe acute exacerbation.
Methods
We prospectively analyzed 37 consecutive patients with acute exacerbation of chronic hepatitis B (accompanied by jaundice and coagulopathy) for clinical outcome and factors that influenced the development of severe acute exacerbation, including viral kinetics.
Results
Fourteen (37.8%) patients progressed to severe acute exacerbation (accompanied by encephalopathy). Multivariate analysis identified serum bilirubin (>5 mg/dl, P = 0.002) as a significant determinant of progression to hepatic failure and prothrombin activity (<45%, P = 0.028) and as a determinant of liver-related death. The hepatitis B virus (HBV) DNA level before therapy was measured in 25 patients. HBV DNA levels increased or did not change from before commencement of treatment in all 11 patients who progressed to severe acute exacerbation. On the other hand, HBV DNA levels did not change or increased in 8 of 14 patients (57%) with acute exacerbation (P = 0.02).
Conclusions
Serum bilirubin and prothrombin activities were significant predictors of clinical outcome in patients with severe acute exacerbation of chronic hepatitis B. Viral kinetics until commencement of therapy can predict the severity of acute exacerbation of chronic hepatitis B.
Similar content being viewed by others
Abbreviations
- AE:
-
Acute exacerbation
- ALT:
-
Alanine aminotransferase
- BCP:
-
Basal core promoter
- CS:
-
Corticosteroid
- HBV:
-
Hepatitis B virus
- IFN:
-
Interferon
- LMV:
-
Lamivudine
- NA:
-
Nucleos(t)ide analogue
- PC:
-
Pre-core
- PT:
-
Prothrombin activity
- SAE:
-
Severe acute exacerbation
References
Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet. 1981;2:1129–33.
Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522–7.
Sheen IS, Liaw YF, Tai DI, Chu CM. Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. Gastroenterology. 1985;89:732–5.
Chu CM, Liaw YF. Increased incidence of fulminant hepatic failure in previously unrecognized HBsAg carriers with acute hepatitis independent of etiology. Infection. 2005;33:136–9.
Levy P, Marcellin P, Martinot-Peignoux M, Degott C, Nataf J, Benhamou JP. Clinical course of spontaneous reactivation of hepatitis B virus infection in patients with chronic hepatitis B. Hepatology. 1990;12:570–4.
Davis GL, Hoofnagle JH, Waggoner JG. Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology. 1984;86:230–5.
Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology. 1975;68:105–12.
Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131:59–68.
Tsubota A, Arase Y, Suzuki Y, Suzuki F, Sezaki H, Hosaka T, et al. Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol. 2005;20:426–32.
Wong VW, Wong GL, Yiu KK, Chim AM, Chu SH, Chan HY, et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol. 2011;54:236–42.
Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology. 2011;53:774–80.
Yuen MF, Sablon E, Hui CK, Li TM, Yuan HJ, Wong DK, et al. Prognostic factors in severe exacerbation of chronic hepatitis B. Clin Infect Dis. 2003;36:979–84.
Jeng WJ, Sheen IS, Liaw YF. Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B. Clin Gastroenterol Hepatol. 2010;8:541–5.
Fujiwara K, Mochida S, Matsui A, Nakayama N, Nagoshi S. Intractable Liver Diseases Study Group of Japan. Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res. 2008;38:646–57.
Mochida S. Indication criteria for liver transplantation for acute liver failure in Japan. Hepatol Res. 2008;38(The 6 Japan Society of Hepatology Single Topic Conference: Liver Failure: Recent Progress and Pathogenesis to Management. 28–29 September 2007, Iwate, Japan):S52–5.
Sjogren MH, Hoofnagle JH, Waggoner JG. Effect of corticosteroid therapy on levels of antibody to hepatitis B core antigen in patients with chronic type B hepatitis. Hepatology. 1987;7:582–5.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–42.
Lok AS, McMahon BJ. Chronic hepatits B. Hepatology. 2007;45:507–39.
Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;22:262–83.
Tsubota A, Arase Y, Suzuki Y, Suzuki F, Hosaka T, Someya T, et al. Benefit of lamivudine therapy and factors associated with clinical outcome in spontaneous severe acute exacerbation of chronic hepatitis B virus infection. Intervirology. 2004;47:335–41.
Chien RN, Lin CH, Liaw YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol. 2003;38:322–7.
Fujiwara K, Yasui S, Yonemitsu Y, Fukai K, Arai M, Imazeki F, et al. Efficacy of combination therapy of antiviral and immunosuppressive drugs for the treatment of severe acute exacerbation of chronic hepatitis B. J Gastroenterol. 2008;43:711–9.
Usuda S, Okamoto H, Imawari H, Baba K, Tsuda F, Miyakawa Y, et al. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in preS2-region product. J Virol Method. 1999;80:97–112.
Tadokoro K, Kobayashi M, Yamaguchi T, Suzuki F, Miyauchi S, Egashira T, et al. Classification of hepatitis B virus genotypes by the PCR-Invader method with genotype-specific probes. J Virol Method. 2006;138:30–9.
Chan HL, Tsang SW, Wong ML, Tse CH, Leung NW, Chan FK, et al. Genotype B hepatitis B virus is associated with severe icteric flare-up of chronic hepatitis B virus infection in Hong Kong. Am J Gastroenterol. 2002;97:2629–33.
Kobayashi M, Ikeda K, Arase Y, Suzuki F, Akuta N, Hosaka T, et al. Change of hepatitis B virus genotypes in acute and chronic infections in Japan. J Med Virol. 2008;80:1880–4.
Imamura T, Yokosuka O, Kurihara T, Kanda T, Fukai K, Imazeki F, et al. Distribution of hepatitis B viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan. Gut. 2003;52:1630–7.
Yuen MF, Sablon E, Wong DK, Yuan HJ, Wong BC, Chan AO, et al. Role of hepatitis B virus genotypes in chronic hepatitis B exacerbation. Clin Infect Dis. 2003;37:593–7.
Ozasa A, Tanaka Y, Orito E, Sugiyama M, Kang JH, Hige S, et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology. 2006;44:326–34.
Baumert TF, Rogers SA, Hasegawa K, Liang TJ. Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest. 1996;98:2268–76.
Ren EX, Xu Z, Liu Y, Li X, Bai S, Ding N, et al. Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis. J Viral Hepat. 2010;17:887–95.
Liang TJ, Hasegawa K, Rimon N, Wands JR, Ben-Porath E. A hepatitis B virus mutant associated with epidemic of fulminant hepatitis. N Engl J Med. 1991;324:175–9.
Yuh CH, Chang YL, Ting LP. Transcriptional regulation of precore and pregenomic RNAs of hepatitis B virus. J Virol. 1992;66:4073–84.
Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology. 2001;120:1009–22.
Higuchi N, Kato M, Kotoh K, Kojima M, Aishima S, Nakamuta M, et al. Methylprednisolone injection via the potal vein suppresses inflammation in acute liver failure induced in rats by lipopolysaccharide and d-galactosamine. Liver Int. 2007;27:1342–8.
Wang M, Shen F, Shi LH, Xi T, Li XF, Chen X, et al. Protective effect of prednisolone on ischemia-induced liver injury in rats. World J Gastroenterol. 2008;14:4332–7.
Dich J, Vind C, Grunnet N. Long-term culture of hepatocytes: effect of hormones on enzyme activities and metabolic capacity. Hepatology. 1998;8:39–45.
Webster GJ, Reignat S, Brown D, Ogg GS, Jones L, Seneviratne SL, et al. Longitudinal analysis of CD8+ cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol. 2004;78:5707–19.
Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, et al. The role of virus-specific CD8+ cells in viral control and liver damage during persistent hepatitis B virus infection. J Exp Med. 2000;191:1269–80.
Chan TM, Wu PC, Li FK, Lai CL, Cheng IKP, Lai KN. Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology. 1998;115:177–81.
Zhang XQ, Jiang L, You JP, Liu YY, Peng J, Zhang HY, et al. Efficacy of short-term dexamethasone therapy in acute-on-chronic pre-liver failure. Hepatol Res. 2011;41:46–53.
Acknowledgment
This study was supported in part by a Grant-in-aid from the Ministry of Health, Labor and Welfare of Japan.
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mori, N., Suzuki, F., Kawamura, Y. et al. Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection. J Gastroenterol 47, 1022–1029 (2012). https://doi.org/10.1007/s00535-012-0561-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00535-012-0561-8